Business Context and Reporting Period
Equillium, Inc. filed this Form 8-K on June 12, 2019, reporting matters voted upon at its annual meeting of stockholders held June 11, 2019. The company is incorporated in Delaware, trades under the symbol EQ on Nasdaq, and had 17,376,236 common shares outstanding as of the April 18, 2019 record date.
Key Financial Metrics
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics. It reports corporate governance matters only.
Material Changes Versus the Prior Comparable Period
The filing does not present comparative financial information or identify material changes in financial performance versus a prior period.
Meeting Results, Outlook, and Other Matters
- 16,667,146 shares were represented at the meeting, equal to approximately 95.92% of shares outstanding as of the record date.
- Stephen Connelly, Ph.D., was elected as a Class I director for a three-year term expiring at the 2022 annual meeting. He received 13,595,404 votes for, 1,770,222 votes withheld, and 1,301,520 broker non-votes.
- Bala S. Manian, Ph.D., was elected as a Class I director for a three-year term expiring at the 2022 annual meeting. He received 13,639,793 votes for, 1,725,833 votes withheld, and 1,301,520 broker non-votes.
- Stockholders ratified KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2019, with 16,666,886 votes for, 260 votes against, and no abstentions or broker non-votes.
- The filing provides no management guidance, operating outlook, contingencies, or unusual financial items.
Important Facts for Investors to Verify
- Confirm the elected directors’ continued service and the composition of the board following the annual meeting.
- Review subsequent filings for any changes involving KPMG LLP or the company’s audited financial statements.
- Consult the company’s periodic reports for financial performance, cash runway, debt, liquidity, clinical development, and other business risks not addressed in this 8-K.